Biomarin Pharmaceutical (BMRN) Non-Current Deferred Tax Liability (2010 - 2016)

Biomarin Pharmaceutical has disclosed Non-Current Deferred Tax Liability across 6 years of filings, most recently posting $143.5 million for Q1 2016.

• Quarterly Non-Current Deferred Tax Liability fell 25.71% year-over-year to $143.5 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $143.5 million (down 25.71% YoY) and the FY2015 annual result came in at $143.5 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability held at $143.5 million in Q1 2016, from $143.5 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $193.2 million in Q1 2015 and troughed at $32.7 million in Q1 2012.
• A 4-year average of $92.5 million and a median of $37.4 million in 2013 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2013 — Non-Current Deferred Tax Liability rose 14.75% — and 2016, when it fell 25.71%.
• Tracing BMRN's Non-Current Deferred Tax Liability over 4 years: stood at $33.3 million in 2012, then rose by 11.7% to $37.2 million in 2013, then soared by 285.93% to $143.5 million in 2015, then changed by 0.0% to $143.5 million in 2016.
• Business Quant data shows BMRN's Non-Current Deferred Tax Liability at $143.5 million in Q1 2016, $143.5 million in Q4 2015, and $193.2 million in Q3 2015.